Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Receives NCI SBIR Grant to Develop In Vitro Liver Toxicity Assays

NEW YORK, Dec. 21 (GenomeWeb News) - Iconix Pharmaceuticals has won a Phase I SBIR grant from the National Cancer Institute to develop new cell-based methods for testing drug candidates for liver toxicity, the company said today.


The grant will allow the Mountain View, Calif.-based company to apply its chemogenomics technology to high-volume testing of drug candidates and environmental chemicals for their potential long-term effects on the liver. Iconix plans to develop in vitro patterns of genomic change that can be used as biomarkers of liver toxicity.


The amount of the grant was not immediately available from the company. The NIH database lists one six-month, $97,654 award for Iconix from the NCI this year entitled "Development of In Vitro Toxicity Expression Assays."

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.